Post-Teva Expert Disclosure Trends In 2 Patent-Rich Districts
Since the U.S. Supreme Court's 2015 Teva Pharmaceuticals USA Inc. v. Sandoz Inc. decision changed the standard of review for extrinsic evidence in patent infringement cases, expert declarations and testimony during...To view the full article, register now.
Already a subscriber? Click here to view full article